Clinical-stage biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) announced on Thursday that it has deployed OpenClaw, an advanced AI-enabled computational platform designed to accelerate drug discovery, improve data-driven decision-making, and unlock value across its therapeutic pipeline.

The launch of OpenClaw establishes a centralised, high-performance platform capable of integrating preclinical and clinical datasets in real time, enabling faster and more efficient research execution, Hoth said.

OpenClaw enables rapid analysis of complex biological data, supporting smarter candidate selection and prioritisation. The platform is expected to enhance development efficiency and improve the probability of technical success across Hoth's programmes. Its modular design allows seamless deployment across dermatology, oncology, and inflammatory disease programmes, standardising workflows and increasing reproducibility at scale.